FDA
-
-
-
-
-
-
-
JPMorgan Starts Enanta Pharmaceuticals (ENTA) at Overweight
-
-
-
-
-
-
-
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C
-
-
-
-
-
-
-
Enanta Pharma (ENTA) Reports Positive Topline Results for EDP-323
-
-
-
-
-
-
-
Enanta Pharma (ENTA) Granted FDA Fast Track Designation for EDP-323
-
-
-
-
-
-
-
Enanta Pharma (ENTA) Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
-
-
-
-
-
-
-
Enanta Pharma (ENTA) Granted FDA Fast Track Designation for EDP-235
-
-
-
-
-
-
-
Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs
-
322,240 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

